Investor Presentaiton
Investor presentation
ADA 2019
Slide 21
Innovation and convenience for patients on basal insulin with
once-weekly insulin LAI287
Rationale for a once-weekly insulin
Provide an efficacious, safe and convenient once-weekly
alternative to once-daily basal insulin for patients with
type 2 diabetes
LAI287 phase 2 programme
2019 H1 |
2019 H2
2020 H1
180
Fewer injections
Lower treatment burden could
lead to higher compliance
T2D, insulin naïve
+ OAD vs glargine
~250 patients, 26 weeks
T2D, insulin naïve
Different titrations vs glargine
~200 patients, 16 weeks
T2D, + OAD
With and without loading dose vs glargine
~150 patients, 16 weeks
Expected phase 2 programme completion: H1 2020
T2D: type 2 diabetes; OAD: oral antidiabetes drugs
novo nordiskView entire presentation